drugset / Trial / NCT06359912
Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia
Phase 1
Unknown
27 enrolled
Allife Medical Science and Technology Co., Ltd.
First Affiliated Hospital Xi'an Jiaotong University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if allogeneic Endothelial Progenitor Cells (EPCs) intravenous infusion to a subject with leg ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain, increase blood flow, and/or cure the leg wound.
Timeline
- Start
- 2024-04
- Primary completion
- 2025-04
- Completion
- 2025-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EPCs | Cell therapy | — | Intravenous |